Activity doxorubicin cisplatin combination chemotherapy patients diffuse malignant pleural mesothelioma Italian Lung Cancer Task Force FONICAP Phase II study Twenty-six symptomatic patients diffuse malignant pleural mesothelioma DMPM Phase II Italian Lung Cancer Task Force FONICAP study activity toxicity doxorubicin cisplatin combination chemotherapy drug schedule doxorubicin cisplatin IV day weeks evaluable patients objective partial responses confidence limits Twelve patients radiologic evidence response clinical improvement objective reduction symptom performance status treatment overall median survival time months Toxicity mild dose reductions suspensions combination doxorubicin cisplatin effective palliation symptomatic patients DMPM 